Table 3: Comparison with conventional injection sclerotherapy.

References Patients ()Follow-up
(months)
Sclerosing agentsEffectiveness
(%)
Complications
(%)
Recurrence
(%)
Additional therapy (%)

Greca et al. 1981 [27] 43125% phenol 70.0030.214.0
Gartell et al. 1985 [12] 109335% phenol 70.0025.7
Walker et al. 1990 [13] 28485% phenol 35.770.264.214.3
Santos et al. 1993 [14] 189485% phenol 60.30.58.522.2
Kanellos et al. 2003 [15] 80485% phenol 17.536.363.030.0
Shi 1997 [16] 21,36136Xiaozhiling 99.04.61.0
Takano et al.
2006 [6]
9512ALTA 94.049.016.0
Tokunaga et al.
2010 [17]
7844–30ALTA 96.01.8
Hachiro et al.
2011 [7]
44829ALTA 3.13.1
Miyamoto et al.
2012 [18]
288–21ALTA 10021.410.7
Yano et al.
2014 [19]
5748ALTA 5322.8
Present study
2015
8327ALTA 97.64.89.68.4

—: results absent or not clearly reported in the text.